These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38692299)

  • 21. CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier.
    Rankin AW; Shah NN
    Med; 2024 Jun; 5(6):482-484. PubMed ID: 38878763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancements and challenges in CAR T cell therapy in autoimmune diseases.
    Schett G; Müller F; Taubmann J; Mackensen A; Wang W; Furie RA; Gold R; Haghikia A; Merkel PA; Caricchio R; D'Agostino MA; Locatelli F; June CH; Mougiakakos D
    Nat Rev Rheumatol; 2024 Sep; 20(9):531-544. PubMed ID: 39107407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
    Mougiakakos D; Krönke G; Völkl S; Kretschmann S; Aigner M; Kharboutli S; Böltz S; Manger B; Mackensen A; Schett G
    N Engl J Med; 2021 Aug; 385(6):567-569. PubMed ID: 34347960
    [No Abstract]   [Full Text] [Related]  

  • 24. [CAR T-cell therapy in rheumatology-What we know so far?].
    Hagen M; Wirsching A; Bohr D; Taubmann J; Müller F; Mackensen A; Grieshaber-Bouyer R; Schett G
    Z Rheumatol; 2024 Aug; 83(6):485-491. PubMed ID: 38780637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
    Daamen AR; Lipsky PE
    Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR immunotherapy in autoimmune diseases: promises and challenges.
    Yu J; Yang Y; Gu Z; Shi M; La Cava A; Liu A
    Front Immunol; 2024; 15():1461102. PubMed ID: 39411714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR T-cell perspectives in lupus.
    Gremese E; Bruno D; Ferraccioli G
    Lancet; 2024 Jul; 404(10450):336. PubMed ID: 39067896
    [No Abstract]   [Full Text] [Related]  

  • 28. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of novel CAR technologies to improve treatment of autoimmune disease.
    Cheever A; Kang CC; O'Neill KL; Weber KS
    Front Immunol; 2024; 15():1465191. PubMed ID: 39445021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future.
    Mougiakakos D
    Signal Transduct Target Ther; 2024 Oct; 9(1):276. PubMed ID: 39379353
    [No Abstract]   [Full Text] [Related]  

  • 31. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Not Available].
    Comte D
    Rev Med Suisse; 2024 Jun; 20(877):1139. PubMed ID: 38836401
    [No Abstract]   [Full Text] [Related]  

  • 33. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.
    Wang W; He S; Zhang W; Zhang H; DeStefano VM; Wada M; Pinz K; Deener G; Shah D; Hagag N; Wang M; Hong M; Zeng R; Lan T; Ma Y; Li F; Liang Y; Guo Z; Zou C; Wang M; Ding L; Ma Y; Yuan Y
    Ann Rheum Dis; 2024 Sep; 83(10):1304-1314. PubMed ID: 38777376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T-cell perspectives in lupus - Authors' reply.
    Schett G; Mackensen A; Mougiakakos D
    Lancet; 2024 Jul; 404(10450):336-337. PubMed ID: 39067897
    [No Abstract]   [Full Text] [Related]  

  • 35. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
    Shah K; Leandro M; Cragg M; Kollert F; Schuler F; Klein C; Reddy V
    Clin Exp Immunol; 2024 Jun; 217(1):15-30. PubMed ID: 38642912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy.
    Guffroy A; Jacquel L; Guffroy B; Martin T
    Joint Bone Spine; 2024 Sep; 91(5):105702. PubMed ID: 38336271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
    Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safer CAR T-Cell Therapy.
    Abbasi J
    JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
    [No Abstract]   [Full Text] [Related]  

  • 40. Frontiers in CAR-T cell therapy for autoimmune diseases.
    Li YR; Lyu Z; Chen Y; Fang Y; Yang L
    Trends Pharmacol Sci; 2024 Sep; 45(9):839-857. PubMed ID: 39147651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.